Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) have been assigned an average rating of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $6.6667.

Several research analysts have weighed in on the stock. UBS Group reiterated a “buy” rating on shares of Innate Pharma in a research note on Tuesday, August 11th. Citigroup raised shares of Innate Pharma from a “buy” rating to an “outperform” rating in a research note on Tuesday, August 11th. Weiss Ratings upgraded shares of Innate Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 26th. BTIG Research upped their price target on shares of Innate Pharma from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Finally, Leerink Partners upgraded Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 price objective for the company in a report on Tuesday, August 11th.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of IPHA. Jane Street Group LLC purchased a new stake in shares of Innate Pharma during the 4th quarter worth about $162,000. OLD Mission Capital LLC bought a new stake in shares of Innate Pharma in the 4th quarter valued at approximately $50,000. Finally, Millennium Management LLC bought a new stake in shares of Innate Pharma in the 4th quarter valued at approximately $36,000. 0.16% of the stock is owned by institutional investors and hedge funds.

Innate Pharma Stock Performance

IPHA stock opened at $2.08 on Friday. The firm has a 50 day simple moving average of $1.95 and a 200 day simple moving average of $1.73. Innate Pharma has a 52 week low of $1.17 and a 52 week high of $2.71.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.